A study utilising preoperative anatomical severity grading in patients undergoing abdominal aortic aneurysm repair has shown that high scores correlate with increased total cost and resource utilisation and the need for adjunctive procedures during endovascular aneurysm repair (EVAR). Because of these adjunctive techniques, the cost of EVAR was US$9,100 higher than open repair in patients with complex anatomies.
Lombard Medical announced on 30 July 2015 the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that has developed an innovative ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal aortic aneurysm anatomies.
Essential Medical has successfully commenced EU clinical studies using its Manta large bore vascular closure device, a vascular closure device designed to seal both 14F and 18F large bore femoral punctures.
Results from the 9th Annual Survey on Observational Research conducted by Continuum Clinical suggest that the pharmaceutical, biotech, and medical device industries are aware of the benefits of observational research in better understanding the real world value of their products. However, they also show that there is continued need to improve the design and implementation of the studies.
Vascutek Ltd has reached a new milestone with the successful implantation of the 1000th Fenestrated Anaconda™ custom AAA stent graft system. The 1000th implant was undertaken by Professor Dominique Midy and Dr Julien Morin from Bordeaux, France on a 62-year-old male who is recovering well following the procedure. The design of the Fenestrated Anaconda™ device for this particular patient was a bifurcated stent graft with 4 fenestrations.
At the International Symposium on Endovascular Therapeutics (SITE; 24–27 June, Barcelona, Spain) Gustavo S Oderich, Mayo Clinic, Rochester, USA, said that there are no definitive studies supporting routine use of embolic protection devices in superficial femoral artery interventions. However, he stated that these devices prevent embolisation during complex procedures.
The first patient has been enrolled and treated in TriVascular Technology’s LUCY study (TriVascular evaluation of females who are underrepresented candidates for abdominal aortic aneurysm sepair).
CREST (Carotid Revascularization Endarterectomy vs Stent Trial) has demonstrated a higher periprocedural stroke and death rate among patients randomised to carotid artery stenting (4.4%) than carotid endarterectomy (2.3%, p=0.005). In previous publications, in an attempt to identify high-risk groups, it has been noted that patients who were older than 70 years did better with carotid endarterectomy than with angioplasty and stenting (p=0.02). In another publication it was noted that women undergoing carotid stenting had a higher event rate than women undergoing carotid endarterectomy.
In July 2015, Jotec received CE mark approval for an enhanced version of the E-vita Thoracic 3G Stent Graft System. According to the company, E-vita Thoracic 3G features an innovative catheter technology “guaranteeing ultimate performance and representing Jotec’s clear commitment to offer cutting-edge technology for best patient care”.
Among older men with low testosterone levels, testosterone administration for three years compared with placebo did not result in a significant difference in the rates of change in atherosclerosis, nor was it associated with improved overall sexual function or health-related quality of life, according to a study in the Journal of the American Medical Association.
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
The first patient has been enrolled in ETNA-AF-Europe (Edoxaban treatment in routine clinical practice – atrial fibrillation – Europe), and ETNA-VTE-Europe (Edoxaban treatment in routine clinical practice – venous thromboembolism – Europe) has commenced.
Results of the landmark CATCH (Comparison of Acute Treatments in Cancer Haemostasis) study were published in The Journal of American Medical Association (JAMA), comparing innohep (tinzaparin), a low-molecular weight heparin (LMWH), with warfarin in patients with cancer-associated thrombosis.
Speaking to Interventional News on the SIRFLOX trial results at the Global Embolization Symposium and Technologies (GEST EU, 24–27 June, Seville, Spain) meeting, Ricky Sharma, professor and honorary consultant of Clinical Oncology at the University of Oxford and Oxford University Hospitals Trust said: “We need to know more about patient selection for radioembolization.
It is important to use the right embolic agent for the job – an embolic agent that is particularly suitable for one indication may not at all be appropriate for another. Robert Morgan, vascular interventional radiologist, St Georges Hospital, London, UK, tells Interventional News why he uses liquid embolic agents, such as ethylene vinyl oxide copolymer (EVOH-based) liquid agents, of which Onyx (Medtronic) is an example, for endoleak embolization.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos